Fate Therapeutics' off the shelf therapy — engineered immune cells trained to target and eliminate the B cells driving scleroderma — improved skin scores in all four patients in a phase 1 trial, with no CAR T related safety events and most treated
Systemic sclerosis is a rare autoimmune disease that thickens the skin, scars internal organs, and shortens lives. Roughly 670,000 people live with it worldwide, and there is no FDA-approved therapy that targets the underlying disease rather than its complications. Boehringer Ingelheim's Ofev (nintedanib) and Genentech's Actemra (tocilizumab) are approved only for the interstitial lung disease that often accompanies scleroderma; neither addresses the skin, vascular, or other organ damage that drives most of the disability.
Fate Therapeutics now has the first early signal that a different mechanism might help. Four of four treatment-resistant systemic sclerosis patients who received a single infusion of the company's off-the-shelf CAR-T therapy, FT819, improved on the standardized skin-thickness score used to track the disease, according to preliminary phase 1 data presented this week at the International Society for Stem Cell Research annual meeting in Montreal. Improvements showed up within roughly three months.
CAR-T, or chimeric antigen receptor T-cell therapy, is the engineered immune-cell treatment most readers know from blood cancers. FT819 is designed to do the same job in autoimmune disease: it hunts and eliminates CD19-positive B cells, the immune cells that produce the autoantibodies driving scleroderma. The "off-the-shelf" label is what makes it structurally different from the standard CAR-T paradigm. Rather than harvesting each patient's T cells and shipping them to a manufacturing facility for a multi-week bespoke engineering run, FT819 is made in advance from a clonally engineered master cell bank of induced pluripotent stem cells (iPSCs), donor-derived adult cells reprogrammed to become many cell types. Fate positions the process as on-demand, scalable, and reproducible across patients, per the company's ISSCR release.
What makes the early readout worth more than its four-patient size is what the investigators deliberately did not do. Standard CAR-T protocols, in cancer and autoimmune settings alike, start with a round of lymphodepleting chemotherapy that wipes out a patient's existing immune cells and makes room for the engineered ones to engraft. That step gates who can receive cell therapy: it requires inpatient infusion center capacity, infection precautions, and weeks of recovery.
FT819 patients were dosed with little to no such conditioning. "We dosed patients with little to no lymphodepleting conditioning before CAR-T dosing," Vaneet Sandhu, M.D., Fate's VP of clinical development, said at ISSCR, per Fierce Biotech. The protocol also let most patients go home the same day: three of four were dosed as outpatients or discharged in under 24 hours.
No cytokine release syndrome, no immune effector cell-associated neurotoxicity syndrome, and no graft-versus-host disease were reported across the four-patient systemic sclerosis cohort, according to Fate's data release. Graft-versus-host disease is the reason most donor-derived cell therapies require careful HLA matching; FT819 sidesteps that risk with a T-cell receptor knockout engineered into the iPSC line.
The four-patient signal is small, single-arm, and short on follow-up, so it is hypothesis-generating rather than confirmatory. The trial, registered as NCT06308978 on ClinicalTrials.gov, has enrolled 30 patients across a basket that also includes lupus and other autoimmune indications, and the next data points will come from more patients and longer follow-up rather than a single pivotal readout. Fate's Q1 2026 financial update sets the runway question for whether the platform can carry to that next dataset.
The structural question this readout raises is whether the conditioning step is, in fact, dispensable in autoimmune disease. If yes, then on-demand, off-the-shelf CAR-T becomes a different commercial and clinical object from the autologous, inpatient-administered therapy that dominates today's cell-therapy market: a single manufacturing run, dispensed when a patient qualifies, given in an outpatient chair. Four patients are a proof of concept, not a verdict. The next cohorts will determine whether the no-lymphodepletion design holds up at scale or only works in the small, treatment-resistant populations where almost anything novel will look promising for a few months.